MedTrace Logo

Long-term Safety of Protopic in Atopic Eczema

NCT00560378 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 789

Last updated 2014-09-18

No results posted yet for this study

Summary

Patients who have participated in previous studies with Tacrolimus ointment for atopic eczema are entitled to enter this four-year follow study to investigate the safety of treatment with Tacrolimus ointment 0.1%

Conditions

  • Dermatitis, Atopic
  • Eczema, Atopic

Interventions

DRUG

Tacrolimus ointment 0.1%

Topical

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-06-30
Completion
2005-06-30

Countries

  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Hungary
  • Ireland
  • Latvia
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560378 on ClinicalTrials.gov